{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:50Z","timestamp":1791912470282,"version":"4.3.4"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00604","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T06:53:34Z","timestamp":1594104814000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":121,"title":["A Practical Approach to Managing Patients With Myasthenia Gravis\u2014Opinions and a Review of the Literature"],"prefix":"10.3389","volume":"11","author":[{"given":"Maria Elena","family":"Farrugia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Goodfellow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/WCO.0000000000000473","article-title":"Myasthenia gravis: new developments in research and treatment","volume":"30","author":"Evoli","year":"2017","journal-title":"Curr Opin Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg."},{"key":"B5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4997\/JRCPE.2019.317","article-title":"The mary walker effect: mary broadfoot walker","volume":"49","author":"McCarter","year":"2019","journal-title":"J R Coll Phys Edinb."},{"key":"B6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jama.1954.03690290011004","article-title":"Studies in myasthenia gravis; preliminary report on therapy with mestinon bromide","volume":"155","author":"Osserman","year":"1954","journal-title":"J Am Med Assoc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","article-title":"Treatment of myasthenia gravis: focus on pyridostigmine","volume":"31","author":"Maggi","year":"2011","journal-title":"Clin Drug Investig."},{"key":"B8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s13181-018-0669-1","article-title":"Cholinergic crisis caused by cholinesterase inhibitors: a retrospective nationwide database study","volume":"14","author":"Ohbe","year":"2018","journal-title":"J Med Toxicol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jen.2017.09.004","article-title":"Neostigmine: not only for the operating room","volume":"44","author":"Gravino","year":"2018","journal-title":"J Emerg Nurs."},{"key":"B10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0825859719869353","article-title":"Administering neostigmine as a subcutaneous infusion: a case report of a patient dying with myasthenia gravis","volume":"35","author":"Hindmarsh","year":"2020","journal-title":"J Palliat Care."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1093\/brain\/awz322","article-title":"\u00df 2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure","volume":"142","author":"Vanhaesebrouck","year":"2019","journal-title":"Brain"},{"key":"B12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2050312118819013","DOI":"10.1177\/2050312118819013","article-title":"Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double-crossover study","volume":"6","author":"Bonanno","year":"2018","journal-title":"SAGE Open Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.nmd.2016.11.009","article-title":"Ephedrine treatment for autoimmune myasthenia gravis","volume":"27","author":"Lipka","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s13311-015-0345-y","article-title":"A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety and tolerability of single doses of Tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis","volume":"12","author":"Sanders","year":"2015","journal-title":"Neurotherapeutics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: association of British neurologists' management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","article-title":"Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis","volume":"396","author":"Kanai","year":"2019","journal-title":"J Neurol Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve."},{"key":"B20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.13544","article-title":"Rationale for the clinical guidelines for myasthenia gravis in Japan","volume":"1413","author":"Murai","year":"2018","journal-title":"Ann NY Acad Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia gravis study group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/nyas.13503","article-title":"The association of British neurologists' myasthenia gravis guidelines","volume":"1412","author":"Sussman","year":"2018","journal-title":"Ann NY Acad Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/CND.0000000000000219","article-title":"Satisfactory response with achieving maintenance low-dose prednisone in generalized myasthenia gravis","volume":"20","author":"Abuzinadah","year":"2018","journal-title":"J Clin Neuromuscul Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"116734","DOI":"10.1016\/j.jns.2020.116734","article-title":"Myasthenia gravis and azathioprine treatment: adverse events related to thiopurine S-methyltransferase (TPMT) polymorphisms","volume":"412","author":"Lorenzoni","year":"2020","journal-title":"J Neurol Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve."},{"key":"B28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"Lavrnic","year":"2005","journal-title":"Acta Neurol Scand."},{"key":"B30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","article-title":"The emerging role of tacrolimus in myasthenia gravis","volume":"8","author":"Cruz","year":"2015","journal-title":"Ther Adv Neurol Disord."},{"key":"B31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"De Feo","year":"2002","journal-title":"Muscle Nerve."},{"key":"B32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ana.410170304","article-title":"Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine","volume":"17","author":"Hohlfeld","year":"1985","journal-title":"Ann Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.0000000000002405","article-title":"Myasthenia gravis exacerbation after discontinuing mycophenolate: a single-center cohort study","volume":"86","author":"Oskarsson","year":"2016","journal-title":"Neurology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/mus.24694","article-title":"Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicentre analysis","volume":"52","author":"Hobson-Webb","year":"2015","journal-title":"Muscle Nerve."},{"key":"B35","first-page":"746","article-title":"Thymektomie bei einem fall von morbus basedowi mit myasthenie [thymectomy in a case of graves' disease with myasthenia]","volume":"25","author":"Schumacher","year":"1912","journal-title":"Mitt Grenzgeb Med Chir."},{"key":"B36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/00000658-193910000-00005","article-title":"Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed","volume":"110","author":"Blalock","year":"1939","journal-title":"Ann Surg."},{"key":"B37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMc1611704","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(18)30392-2","article-title":"Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial","volume":"18","author":"Wolfe","year":"2019","journal-title":"Lancet Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/0003-4975(93)90963-I","article-title":"Thoracoscopic surgery: the belgian experience","volume":"56","author":"Coosemans","year":"1993","journal-title":"Ann Thorac Surg."},{"key":"B40","first-page":"185","article-title":"Thymoma. The use of minimally invasive resection techniques","volume":"4","author":"Kaiser","year":"1994","journal-title":"Chest Surg Clin N Am."},{"key":"B41","first-page":"378","article-title":"Extended thymectomy, without sternotomy, performed by cervicotomy and thoracoscopic technique in the treatment of myasthenia gravis","volume":"79","author":"Novellino","year":"1994","journal-title":"Int Surg"},{"key":"B42","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0003-4975(02)04296-0","article-title":"Totally endoscopic robotic thymectomy for myasthenia gravis","volume":"75","author":"Ashton","year":"2003","journal-title":"Ann Thorac Surg."},{"key":"B43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.21037\/acs.2019.02.04","article-title":"A systematic review of robotic versus open and video assisted thoracoscopic surgery (VATS) approaches for thymectomy","volume":"8","author":"O'Sullivan","year":"2019","journal-title":"Ann Cardiothorac Surg."},{"key":"B44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.asjsur.2016.09.006","article-title":"Comparative clinical outcomes after thymectomy for myasthenia gravis: thoracoscopic versus trans-sternal approach","volume":"41","author":"Siwachat","year":"2018","journal-title":"Asian J Surg."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1093\/ejcts\/ezy239","article-title":"Video-assisted thoracoscopic surgery versus open surgery for Stage I thymic epithelial tumours: a propensity score-matched study","volume":"54","author":"Gu","year":"2018","journal-title":"Eur J Cardiothorac Surg."},{"key":"B46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/ejcts\/ezy075","article-title":"Comparing robotic and trans-sternal thymectomy for early-stage thymoma: a propensity score-matching study","volume":"54","author":"Marulli","year":"2018","journal-title":"Eur J Cardiothorac Surg."},{"key":"B47","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/icvts\/ivz320","article-title":"Video-assisted thoracoscopic thymectomy is feasible for large thymomas: a propensity-matched comparison","volume":"30","author":"Weng","year":"2020","journal-title":"Interact Cardiovasc Thorac Surg."},{"key":"B48","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1072-7515(01)00795-5","article-title":"Analysis of thymectomy for myasthenia gravis in older patients: a 20-year single institution experience","volume":"192","author":"Abt","year":"2001","journal-title":"J Am Coll Surg."},{"key":"B49","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1007\/s00415-019-09222-2","article-title":"Effect of thymectomy in elderly patients with non-thymomatous generalized myasthenia gravis","volume":"266","author":"Kim","year":"2019","journal-title":"J Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/mus.26404","article-title":"Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis","volume":"59","author":"Clifford","year":"2019","journal-title":"Muscle Nerve."},{"key":"B51","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.autrev.2018.07.011","article-title":"Characterization of the thymus in Lrp4 myasthenia gravis: four cases","volume":"18","author":"Koneczny","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1586\/era.13.54","article-title":"Thymoma and radiation therapy: a systematic review of medical treatment","volume":"13","author":"Giannopoulou","year":"2013","journal-title":"Expert Rev Anticancer Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jtho.2017.01.002","article-title":"The impact of postoperative radiotherapy for thymoma and thymic carcinoma","volume":"12","author":"Jackson","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","article-title":"Systemic treatments for thymoma and thymic carcinoma: a systematic review","volume":"126","author":"Berghmans","year":"2018","journal-title":"Lung Cancer."},{"key":"B56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","article-title":"Ocular myasthenia","volume":"36","author":"Al-Haidar","year":"2018","journal-title":"Neurol Clin."},{"key":"B57","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ICU.0000000000000526","article-title":"Ocular myasthenia gravis: an update on diagnosis and treatment","volume":"29","author":"Fortin","year":"2018","journal-title":"Curr Opin Ophthalmol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.clinph.2019.04.005","article-title":"Guidelines for single fiber EMG","volume":"130","author":"Sanders","year":"2019","journal-title":"Clin Neurophysiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0960-8966(00)00173-5","article-title":"Therapeutic options in ocular myasthenia gravis","volume":"11","author":"Evoli","year":"2001","journal-title":"Neuromuscul Disord."},{"key":"B60","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/WNO.0b013e3182536558","article-title":"Safety of prednisone for ocular myasthenia gravis","volume":"32","author":"Bruce","year":"2012","journal-title":"J Neuroophthalmol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11940-011-0151-8","article-title":"Treatment of ocular myasthenia gravis","volume":"14","author":"Haines","year":"2012","journal-title":"Curr Treat Opt Neurol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur J Neurol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","article-title":"Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up","volume":"256","author":"Kupersmith","year":"2009","journal-title":"J Neurol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/CND.0b013e31821c5634","article-title":"Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response","volume":"13","author":"Mittal","year":"2011","journal-title":"J Clin Neuromuscul Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/mus.26172","article-title":"Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies","volume":"58","author":"Europa","year":"2018","journal-title":"Muscle Nerve."},{"key":"B67","doi-asserted-by":"publisher","first-page":"12062","DOI":"10.1073\/pnas.211257298","article-title":"Extraocular muscle is defined by a fundamentally distinct gene expression profile","volume":"98","author":"Porter","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1749-6632.2011.06123.x","article-title":"Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles","volume":"1233","author":"Serra","year":"2011","journal-title":"Ann NY Acad Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1167\/iovs.10-5937","article-title":"Myosin heavy chain expression in mouse extraocular muscle: more complex than expected","volume":"51","author":"Zhou","year":"2010","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1196\/annals.1405.037","article-title":"Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?","volume":"1132","author":"Soltys","year":"2008","journal-title":"Ann NY Acad Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nmd.2019.03.009","article-title":"A review of the histopathological findings in myasthenia gravis: clues to the pathogenesis of treatment-resistance in extraocular muscles","volume":"29","author":"Europa","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B72","doi-asserted-by":"publisher","first-page":"CD005081","DOI":"10.1002\/14651858.CD005081.pub3","article-title":"Medical and surgical treatment for ocular myasthenia","volume":"12","author":"Benatar","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"B73","first-page":"730","article-title":"Ocular divergence mechanisms","volume":"68","author":"Jampolsky","year":"1970","journal-title":"Trans Am Ophthalmol Soc."},{"key":"B74","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/eye.1993.123","article-title":"Diagrammatic representation of strabismus","volume":"7","author":"Vivian","year":"1993","journal-title":"Eye (Lond.)."},{"key":"B75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2017.09.036","article-title":"A retrospective study of acetylcholine receptor antibody positive ocular myasthenia in the West of Scotland","volume":"382","author":"Farrugia","year":"2017","journal-title":"J Neurol Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/08820538.2017.1284871","article-title":"Ptosis surgery in patients with myasthenia gravis- a useful adjunct to medical therapy","volume":"33","author":"Brogan","year":"2018","journal-title":"Semin Ophthalmol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.jocn.2015.05.032","article-title":"Myasthenia gravis exacerbation with low dose ocular botulinum toxin for epiphoria","volume":"22","author":"Watts","year":"2015","journal-title":"J Clin Neurosci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0022-5223(96)70264-7","article-title":"Delayed remission after thymectomy for myasthenia gravis of the purely ocular type","volume":"112","author":"Nakamura","year":"1996","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B79","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1067\/mtc.2001.116191","article-title":"Thymectomy in the treatment of ocular myasthenia gravis","volume":"122","author":"Roberts","year":"2001","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.athoracsur.2011.08.001","article-title":"Extended transsternal thymectomy for the treatment of ocular myasthenia gravis","volume":"92","author":"Liu","year":"2011","journal-title":"Ann Thorac Surg."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jtcvs.2012.12.053","article-title":"Outcomes after thymectomy in class I myasthenia gravis","volume":"145","author":"Mineo","year":"2013","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10072-017-3058-7","article-title":"Thymectomy is a beneficial therapy for patients with non-thymomatous ocular myasthenia gravis: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2017","journal-title":"Neurol Sci."},{"key":"B83","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1212\/WNL.52.3.447","article-title":"Course and treatment of myasthenia gravis during pregnancy","volume":"52","author":"Batocchi","year":"1999","journal-title":"Neurology."},{"key":"B84","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00003081-199103000-00012","article-title":"Myasthenia gravis in mothers and their newborns","volume":"34","author":"Plauch\u00e9","year":"1991","journal-title":"Clin Obstet Gynecol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","article-title":"Myasthenia in pregnancy : best practice guidelines for a UK multispecialty working group","volume":"85","author":"Norwood","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/ene.13788","article-title":"Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence","volume":"25","author":"Gilhus","year":"2018","journal-title":"Eur J Neurol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ncl.2018.01.005","article-title":"An update: myasthenia gravis and pregnancy","volume":"36","author":"Hamel","year":"2018","journal-title":"Neurol Clin."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1212\/01.WNL.0000082725.21444.EC","article-title":"Myasthenia gravis. Consequences for pregnancy, delivery and the newborn","volume":"61","author":"Hoff","year":"2003","journal-title":"Neurology."},{"key":"B89","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nmd.2017.01.021","article-title":"Clinical follow-up of pregnancy in myasthenia gravis patients","volume":"27","author":"Ducci","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"B90","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/jog.13922","article-title":"Management of labor and delivery in myasthenia gravis: a new protocol","volume":"45","author":"Tsurane","year":"2019","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/088307389200700202","article-title":"Transient neonatal myasthenia gravis","volume":"7","author":"Papazian","year":"1992","journal-title":"J. Child Neurol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1212\/NXI.0000000000000057","article-title":"Fetal acetylcholine receptor inactivation syndrome: a myopathy due to maternal antibodies","volume":"2","author":"Hacohen","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B93","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1468-1331.1998.520137.x","article-title":"The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit","volume":"5","author":"O'Riordan","year":"1998","journal-title":"Eur J Neurol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1385\/NCC:3:3:213","article-title":"Risk of extubation failure in patients with myasthenic crisis","volume":"3","author":"Rabinstein","year":"2005","journal-title":"Neurocrit Care."},{"key":"B95","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/NRL.0000000000000026","article-title":"IVIG versus PLEX in the treatment of worsening myasthenia gravis: what is the evidence? A critically appraised topic","volume":"19","author":"Dhawan","year":"2015","journal-title":"Neurologist."},{"key":"B96","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","article-title":"Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study","volume":"13","author":"Heatwole","year":"2011","journal-title":"J Clin Neuromuscul Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/mus.23508","article-title":"A Retrospective study of complications of therapeutic plasma exchange in myasthenia","volume":"47","author":"Guptill","year":"2013","journal-title":"Muscle Nerve"},{"key":"B99","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist."},{"key":"B100","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2169\/internalmedicine.44.572","article-title":"Increase in incidence of elderly-onset patients with myasthenia gravis in nagano prefecture","volume":"44","author":"Matsuda","year":"","journal-title":"Jpn Intern Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/mus.23964","article-title":"Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing","volume":"48","author":"Alkhawajah","year":"2013","journal-title":"Muscle Nerve."},{"key":"B102","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000500268","article-title":"A prospective study of the incidence of myasthenia gravis in the east midlands of England","volume":"53","author":"Maddison","year":"2019","journal-title":"Neuroepidemiology."},{"key":"B103","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","article-title":"Epidemiology of myasthenia gravis in Ontario, Canada","volume":"26","author":"Breiner","year":"2016","journal-title":"Neuromuscul Disord."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nrleng.2014.09.010","article-title":"Prevalence of myasthenia gravis in the catalan county of Osona","volume":"32","author":"Aragon\u00e8s","year":"2017","journal-title":"Neurologia."},{"key":"B105","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0733-8619(18)30096-3","article-title":"The epidemiology of myasthenia gravis","volume":"12","author":"Phillips","year":"1994","journal-title":"Neurol Clin"},{"key":"B106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archneur.56.1.25","article-title":"Late-onset myasthenia gravis: a changing scene","volume":"56","author":"Aarli","year":"1999","journal-title":"Arch Neurol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4137\/JCM.S29601","article-title":"Treatment of myasthenia gravis in patients with elderly onset at advanced age","volume":"6","author":"Nishikawa","year":"2015","journal-title":"Jpn Clin Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1212\/WNL.0000000000000804","article-title":"Increased risk of osteoporosis in patients with myasthenia gravis: a population-based cohort study","volume":"83","author":"Yeh","year":"2014","journal-title":"Neurology."},{"key":"B109","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/nyas.13562","article-title":"Rituximab in myasthenia gravis: a \u201cto be or not to be\u201d inhibitor of T cell function","volume":"1413","author":"Marino","year":"2018","journal-title":"Ann NY Acad Sci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve."},{"key":"B111","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/JND-180300","article-title":"Efficacy of rituximab in refractory generalized anti-AChR myasthenia gravis","volume":"5","author":"Landon-Cardinal","year":"2018","journal-title":"J Neuromuscul Dis."},{"key":"B112","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J Neurol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00edaz-Manera","year":"2012","journal-title":"Neurology."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis","author":"Brauner","year":"2020","journal-title":"JAMA Neurol"},{"key":"B115","first-page":"79","article-title":"Delayed-onset and long-lasting severe neutropenia due to rituximab","volume":"134","author":"Hofer","year":"2004","journal-title":"Swiss Med Wkly."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1097\/01.tp.0000184275.81396.45","article-title":"Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation","volume":"80","author":"Mitsuhata","year":"2005","journal-title":"Transplantation."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1592\/phco.2005.25.8.1151","article-title":"Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review","volume":"25","author":"Motl","year":"2005","journal-title":"Pharmacotherapy."},{"key":"B118","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve."},{"key":"B119","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","article-title":"Rituximab in AChR subtype of myasthenia gravis: systematic review","volume":"91","author":"Di Stefano","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B120","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generlaized myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multi-centre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","article-title":"Eculizumab improves fatigue in refractory generalized myasthenia gravis","volume":"28","author":"Andersen","year":"2019","journal-title":"Qual Life Res."},{"key":"B123","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S1474-4422(17)30363-0","article-title":"Eculizumab: a treatment option for myasthenia gravis?","volume":"16","author":"Gilhus","year":"2017","journal-title":"Lancet Neurol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology."},{"key":"B126","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/14740338.2018.1513487","article-title":"The safety of bortezomib for the treatment of multiple myeloma","volume":"17","author":"Cengiz Seval","year":"2018","journal-title":"Expert Opin Drug Saf."},{"key":"B127","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.leukres.2017.09.020","article-title":"Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease","volume":"62","author":"Guerrero-Garcia","year":"2017","journal-title":"Leuk Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience","volume":"10","author":"Schneider-Gold","year":"2017","journal-title":"Ther Adv Neurol Disord."},{"key":"B129","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annrmp.2006.04.016","article-title":"Fatigue and neuromuscular diseases","volume":"49","author":"F\u00e9asson","year":"2006","journal-title":"Ann Readapt Med Phys."},{"key":"B130","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1212\/WNL.0b013e31827f07be","article-title":"Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy","volume":"80","author":"Kluger","year":"2013","journal-title":"Neurology."},{"key":"B131","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2377-13-132","article-title":"Fatigue in myasthenia gravis: is it more than muscular weakness?","volume":"13","author":"Elsais","year":"2013","journal-title":"BMC Neurol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/mus.25386","article-title":"Assessment of physical fatigability and fatigue perception in myasthenia gravis","volume":"55","author":"Jordan","year":"2017","journal-title":"Muscle Nerve."},{"key":"B133","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/mus.25540","article-title":"Cognitive fatigue in patients with myasthenia gravis","volume":"56","author":"Jordan","year":"2017","journal-title":"Muscle Nerve."},{"key":"B134","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jns.2017.08.3250","article-title":"Body composition and adipokines plasma levels in patients with myasthenia gravis treated with high cumulative glucocorticoid dose","volume":"381","author":"Braz","year":"2017","journal-title":"J Neurol Sci."},{"key":"B135","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s13760-017-0787-6","article-title":"Is there any relationship between quality of life and polysomnographically detected sleep parameters\/disorders in stable myasthenia gravis?","volume":"118","author":"Tascilar","year":"2018","journal-title":"Acta Neurol Belg."},{"key":"B136","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cyto.2012.02.015","article-title":"Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression","volume":"58","author":"Illi","year":"2012","journal-title":"Cytokine."},{"key":"B137","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3233\/JND-170299","article-title":"A physical and psychological approach to managing fatigue in myasthenia gravis: a pilot study","volume":"5","author":"Farrugia","year":"2018","journal-title":"J Neuromuscul Dis."},{"key":"B138","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JND-180355","article-title":"Pattern of habitual physical exercise in myasthenia gravis patients","volume":"6","author":"O'Connor","year":"2019","journal-title":"J Neuromuscul Dis."},{"key":"B139","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/mus.25493","article-title":"Physical exercise in myasthenia gravis is safe and improves neuromuscular parameters and physical performance-based measures: a pilot study","volume":"56","author":"Westerberg","year":"2017","journal-title":"Muscle Nerve."},{"key":"B140","doi-asserted-by":"publisher","first-page":"e11510","DOI":"10.1097\/MD.0000000000011510","article-title":"The impact of physical exercise on neuromuscular function in myasthenia gravis patients: a single-subject design study","volume":"97","author":"Westerberg","year":"2018","journal-title":"Medicine."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0000000000001008","article-title":"Both aerobic exercise and cognitive\u2013behavioural therapy reduce chronic fatigue in FSHD: an RCT","volume":"83","author":"Voet","year":"2014","journal-title":"Neurology."},{"key":"B142","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13063-015-0737-7","article-title":"Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial","volume":"16","author":"van Engelen","year":"2015","journal-title":"Trials"},{"key":"B143","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2340\/16501977-2247","article-title":"Cognitive behaviour therapy for reducing fatigue in post-polio syndrome and in facioscapulohumeral dystrophy: a comparison","volume":"49","author":"Koopman","year":"2017","journal-title":"J Rehabil Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.25552","article-title":"Exercise in myasthenia gravis: a feasibility study of aerobic and resistance training","volume":"56","author":"Rahbek","year":"2017","journal-title":"Muscle Nerve."},{"key":"B145","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1212\/WNL.0b013e318228c0c7","article-title":"Guided self-help for functional (psychogenic) symptoms: a randomized controlled efficacy study","volume":"77","author":"Sharpe","year":"2011","journal-title":"Neurology."},{"key":"B146","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/thx.49.7.703","article-title":"Breathing pattern and central ventilatory drive in mild and moderate generalized myasthenia gravis","volume":"49","author":"Garc\u00eda Rio","year":"1994","journal-title":"Thorax."},{"key":"B147","doi-asserted-by":"publisher","first-page":"105894","DOI":"10.1016\/j.rmed.2020.105894","article-title":"The impact of dysfunctional breathing on the level of asthma control in difficult asthma","volume":"163","author":"Sedeh","year":"2020","journal-title":"Respir Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e032984","DOI":"10.1136\/bmjopen-2019-032984","article-title":"Protocol for a multicenter randomised controlled trial to investigate the effect on asthma-related quality of life from breathing retraining in patients with incomplete asthma control attending specialist care in Denmark","volume":"9","author":"Andreasson","year":"2019","journal-title":"BMJ Open."},{"key":"B149","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.rmed.2018.09.001","article-title":"Effects of long-term respiratory muscle endurance training on respiratory and functional outcomes in patients with myasthenia gravis","volume":"144","author":"Freitag","year":"2018","journal-title":"Respir Med."},{"key":"B150","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve."},{"key":"B151","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF00315656","article-title":"A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy","volume":"237","author":"Mantegazza","year":"1990","journal-title":"J Neurol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0022-510X(91)90260-E","article-title":"Prognosis of myasthenia gravis: a multicentre follow-up study of 844 patients","volume":"106","author":"Beghi","year":"1991","journal-title":"J Neurol Sci."},{"key":"B153","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1196\/annals.1254.054","article-title":"Myasthenia gravis (MG): epidemiological data and prognostic factors","volume":"998","author":"Mantegazza","year":"2003","journal-title":"Ann NY Acad Sci."},{"key":"B154","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/00207454.2016.1257993","article-title":"Prognosis of thymectomy in myasthenia gravis patients with thymus hyperplasia","volume":"127","author":"Yang","year":"2017","journal-title":"Int J Neurosci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00604\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T06:53:37Z","timestamp":1594104817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00604\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":154,"alternative-id":["10.3389\/fneur.2020.00604"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00604","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]},"article-number":"604"}}